KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $490.6 million.

  • Adaptive Biotechnologies' Liabilities and Shareholders Equity fell 1215.67% to $490.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 1597.47%. This contributed to the annual value of $539.4 million for FY2024, which is 1841.65% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Liabilities and Shareholders Equity stood at $490.6 million, which was down 1215.67% from $496.6 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q1 2021 and a low of $490.6 million during Q3 2025
  • For the 5-year period, Adaptive Biotechnologies' Liabilities and Shareholders Equity averaged around $745.4 million, with its median value being $764.5 million (2023).
  • As far as peak fluctuations go, Adaptive Biotechnologies' Liabilities and Shareholders Equity skyrocketed by 2254.09% in 2021, and later plummeted by 2350.01% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' Liabilities and Shareholders Equity (Quarter) stood at $923.3 million in 2021, then decreased by 7.23% to $856.6 million in 2022, then decreased by 22.82% to $661.1 million in 2023, then dropped by 18.42% to $539.4 million in 2024, then fell by 9.04% to $490.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $490.6 million in Q3 2025, compared to $496.6 million in Q2 2025 and $510.9 million in Q1 2025.